Monitor for upcoming securities offerings under this shelf registration, likely necessary to avoid insolvency. The company's low market cap ($9M) and cash runway concerns suggest any offering will be dilutive and potentially at unfavorable terms.
Price Chart
Executive Summary
Aprea Therapeutics filed an S-3/A amendment solely to update the auditor's consent from EisnerAmper. The filing confirms the company's shelf registration remains active for future securities offerings, but no new offering details are provided. The auditor's report notes substantial doubt about the company's ability to continue as a going concern due to insufficient cash to fund operations beyond the next 12 months.
Key Facts
- S-3/A filing is a pre-effective amendment solely to update auditor consent (Exhibit 23.2) from EisnerAmper
- No changes were made to the prospectus or offering terms
- Auditor's report includes an explanatory paragraph about substantial doubt regarding the company's ability to continue as a going concern
- Company previously disclosed in its 10-Q that its $13.7M cash balance as of September 30, 2025, is insufficient to fund operations for the next 12 months
- The shelf registration allows for future offerings of up to $150M in securities, but no specific offering is announced in this filing
Financial Impact
The filing itself has no immediate financial impact as it only updates an auditor consent. However, it confirms the company's shelf registration is active, signaling potential future dilutive offerings to address liquidity concerns.
Risk Factors
- Substantial doubt about going concern status due to insufficient cash
- High risk of dilutive equity offerings in the near term
- Potential for down-round financing given low market cap and cash position
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001104659-26-029519 |
| Document: tm268966d1_ex23-2.htm | 0001104659-26-029519 |
| Document: 0001104659-26-029519-index-headers.html | 0001104659-26-029519 |
| Document: 0001104659-26-029519-index.html | 0001104659-26-029519 |
| Document: 0001104659-26-029519.txt | 0001104659-26-029519 |
| CONTEXT: 10-Q (2025-11-12) | 0001104659-25-109867 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 8w ago | 8-K | $0.8386 | awaiting T+60 | — | $0.5180 (−38.23%) |
Aug 12, 2026 10w ago | 8-K | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
Aug 12, 2026 10w ago | Press Release | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
May 13, 2026 23w ago | 8-K | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
May 13, 2026 23w ago | Press Release | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
Apr 30, 2026 25w ago | DEFA14A | $0.8000 $0.6247 | ▲ +21.91% | ▲ +25.02% | $0.5180 (+35.25%) |
Apr 22, 2026 26w ago | S-3 | $0.8840 $0.6690 | ▲ +24.32% | ▲ +29.34% | $0.5180 (+41.40%) |
Apr 21, 2026 26w ago | Press Release | $0.9070 $0.6900 | ▼ −23.93% | ▼ −30.82% | $0.5180 (−42.89%) |
Mar 31, 2026 29w ago | Insider Cluster | $0.7630 $0.7900 | ▲ +3.54% | ▼ −8.84% | $0.5180 (−32.11%) |
Mar 20, 2026 31w ago | EFFECT | $0.7620 $0.6990 | ▼ −8.27% | ▼ −22.69% | $0.5180 (−32.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers